Medicare slashes 340B payments, broadens site-neutral policies in proposed 2027 payment rule

CMS proposed reductions to Medicare reimbursement under the 340B drug program and expanded site-neutral payment policies for 2027, aligning with Trump administration priorities for healthcare cost control. The changes significantly impact medical device and pharmaceutical acquisition costs in healthcare settings.